SCHEMBL13290643

SCHEMBL13290643

C=CC[Si](C)(C)Oc1ccc(C(C)(C)C)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.42
POLB P06746 4/20 0.42
LMNA P02545 2/20 0.42
ATM Q13315 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
ALDH1A1 P00352 3/20 0.38
MAPK1 P28482 2/20 0.38
NPC1 O15118 1/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
NR1H2 P55055 1/20 0.37
NR1H3 Q13133 1/20 0.37
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
APP P05067 1/20 0.36
MAOB P27338 1/20 0.36
AOC3 Q16853 1/20 0.36
ALOX15 P16050 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13290644 0.83 RAB9A (0.42) RAB9APOLBLMNAATML3MBTL1
SCHEMBL28447705 0.79 TDP1 (0.39) RAB9APOLBSMN1; SMN2ALDH1A1MAPK1
SCHEMBL13822383 0.78 CA4 (0.34) RAB9APOLBL3MBTL1SMN1; SMN2MAPT
SCHEMBL22580517 0.77 RAB9A (0.41) RAB9APOLBLMNAATML3MBTL1
SCHEMBL13290652 0.75 RAB9A (0.44) RAB9APOLBLMNAATML3MBTL1
SCHEMBL22540655 0.74 RAB9A (0.42) RAB9APOLBLMNAATML3MBTL1
SCHEMBL13290647 0.74 RAB9A (0.43) RAB9APOLBLMNAATML3MBTL1
SCHEMBL16048013 0.73 RAB9A (0.48) RAB9APOLBLMNAATML3MBTL1
SCHEMBL22540719 0.72 CA1 (0.40) RAB9APOLBLMNAATML3MBTL1
SCHEMBL22580519 0.71 RAB9A (0.40) RAB9APOLBLMNAATML3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7741289-B2 Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof SCHERING CORPORATION (US) 2010-06-22 US disclosed
US-20080207585-A1 Substituted Azetidinone Compounds, Processes for Preparing the Same, Formulations and Uses Thereof SCHERING CORPORATION (US) 2008-08-28 US disclosed
US-7368563-B2 Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof SCHERING CORPORATION (US) 2008-05-06 US disclosed
US-20070155675-A1 Substituted azetidinone compunds, processes for preparing the same, formulations and uses thereof SCHERING CORPORATION (US) 2007-07-05 US disclosed
US-7235543-B2 Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof SCHERING CORPORATION (US) 2007-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207585-A1 Substituted Azetidinone Compounds, Processes for Preparing the Same, Formulations and Uses Thereof CYP46A1, NPC1L1, PCSK9 RAB9A 2086/4885POLB 4689/4885LMNA 818/4885
US-20070155675-A1 Substituted azetidinone compunds, processes for preparing the same, formulations and uses thereof APOB, NPC1L1, CYP46A1 RAB9A 3802/4885POLB 3934/4885LMNA 1989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.